|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expressions of VEGF receptors and their ligands significantly differed between malignant ovarian tumors and paired distant metastases.
|
31200683 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CircRhoC promotes tumorigenicity and progression in ovarian cancer by functioning as a miR-302e sponge to positively regulate VEGFA.
|
31639291 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) promotes progression of ovarian cancer.
|
30348916 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate mRNA expression of NCK2, integrins and VEGFA in OvCa cell lines, qRT-PCR was performed.
|
29218693 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
|
30066848 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
A plethora of growth factors including Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) stimulated signaling pathways regulate the invasive/metastatic behavior of ovarian tumors contributing to its aggressiveness.
|
29904943 |
2018 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Oxytocin inhibits ovarian cancer metastasis by repressing the expression of MMP-2 and VEGF.
|
29721047 |
2018 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present meta-analysis indicated that positive/high expression of tissue VEGF may have a close association with survival of ovarian cancer.
|
30093968 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC).
|
27852039 |
2017 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VEGF expression in ovarian cancer induced MDSCs, inhibited local immunity, and contributed to poor prognosis.
|
27401249 |
2017 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis.
|
29069849 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGFA stimulated sphere formation only in the ALDH1<sup>+</sup> subpopulation and increased OVCA-initiating cells and tumor formation <i>in vivo</i> through Bmi1.
|
28179359 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the relationship among SPARC, VEGFs and lymph node metastasis in ovarian cancer.
|
29075785 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day.
|
27943222 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we demonstrated that the upregulation of SP1 enhanced expression of VEGF promoting the angiogenesis and migration of trastuzumab-resistant ovarian cancer cell line SKOV3-T. Our in vitro and in vivo results both gave evidence that the SP1-VEGF axis was responsible for the enhanced malignancy, angiogenesis and migration in the acquired trastuzumab-resistant ovarian cancer cell model.
|
29048687 |
2017 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
|
28301874 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
• Reduced ADCs correlate with prognostic markers: poor differentiation and high Ki-67 expression • ADCs also significantly correlated with VEGF protein expression in primary tumours • Lower ADC values are associated with poorer survival in ovarian cancer • Whole lesion single plane-ROI ADCs may be used as a prognostic biomarker in OC.
|
28289938 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings highlighted the prognostic role of VEGF-mediated angiogenesis in ovarian cancer, and proposed a VEGF-dependent gene signature as a molecular basis for developing novel diagnostic strategies to aid patient selection for VEGF-targeted agents.
|
27498762 |
2016 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cessation of therapy with pazopanib, bevacizumab, and the human and murine anti-VEGF antibody B20 was associated with substantial tumor growth in mouse models of ovarian cancer.
|
27064283 |
2016 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the C-terminus of IGFBP-5 exerts anti-cancer activity by inhibiting angiogenesis via regulation of the Akt/ERK and NF-kB-VEGF/MMP-9 signaling pathway, and might be considered as a novel angiogenesis inhibitor for the treatment of ovarian cancer.
|
28008951 |
2016 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGF concentrations in ascites significantly increased in c-MYC-induced ovarian cancer, whereas the concentrations of inflammatory cytokines in ascites were significantly high in KRAS-induced ovarian cancer and were accompanied by an increased number of neutrophils in ascites.
|
27483433 |
2016 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we observed a differential response of OC cells to anti-VEGF agent bevacizumab (BV) by using xenograft models.
|
26531153 |
2016 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results show that VEGF111b, as a new member of VEGFxxxb family, with similar properties to VEGF165b, plays potent anti-tumor effect in vitro and in vivo that can target the VEGF-R2 and its signaling pathway to inhibit ovarian tumor growth.
|
25990504 |
2015 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent evidence suggests that proangiogenic factors other than the widely known, potent angiogenic factor vascular endothelial growth factor may mediate growth and metastasis of ovarian cancer.
|
26610586 |
2015 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis provides supportive evidence that the VEGF +936 C/T polymorphism may influence the risk for the development of OC in a protective model among whites.
|
25835351 |
2015 |